Evommune, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Judah Frommer from Morgan Stanley maintained a Buy rating on the stock and has a $54.00 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Judah Frommer has given his Buy rating due to a combination of factors that collectively strengthen the investment case for Evommune, Inc. SEPN’s Phase 1 data for SEP-631, a competing MRGPRX2 modulator, demonstrated clean safety and clear target engagement in healthy volunteers, which Frommer views as independent confirmation that this target and mechanism are clinically meaningful and aligned with Evommune’s strategy.
At the same time, SEPN’s development timeline appears to trail Evommune’s EVO756 program by roughly one and a half to two years, as Evommune has already begun its Phase 2b trial in chronic spontaneous urticaria while SEPN expects to start a similar study only in the second half of 2026. Frommer also notes that Evommune is actively assessing once-daily and extended-release dosing options for EVO756, which could enhance convenience and differentiation, further reinforcing the competitive positioning that supports a Buy recommendation.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVMN in relation to earlier this year.